Oculis to buy Privosegtor rights from Accure Therapeutics for $3.8 million and up to 2,050,000 shares
AI Market Summary
Oculis signed an asset purchase agreement to acquire Accure's global rights to Privosegtor (and, in a later closing, ACT-02) for $3.8m cash plus up to 2.05m shares tied to lockups and milestones. The deal terminates the prior license, potentially reducing future royalties and increasing Oculis' economic upside, but both assets remain unapproved and closings are conditional, limiting near-term broader market relevance.
Impact level
● Low
Affected assets
NCCOGOLD2USD/USDT-0.44%
AI Insight · NCCOGOLD2USD/USDTAI Insight
● Neutral
Trade now
⚠️ AI-generated insights are based on news content and are provided for informational purposes only. They do not constitute investment advice or represent the views of BingX. Investing involves risk. Please trade responsibly.
Oculis has signed an asset purchase agreement with Accure Therapeutics to acquire the worldwide development and commercial rights to Privosegtor and, in a separate closing, ACT02. The consideration includes a $3.8 million upfront cash payment and up to 2,050,000 Oculis ordinary shares, with lockup and milestone-based vesting terms. Privosegtor is an investigational neuroophthalmology drug candidate that has not received regulatory approval for commercial use in any country, while ACT02 is an early-stage preclinical neurology candidate. Oculis said the deal is intended to strengthen its pipeline and strategic position in neuroophthalmology.
